[
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Moderna, Inc. (MRNA) on Substack by Natan. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc. (MRNA)’s share was trading at $42.05 as of Nov 26th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, a biotech leader renowned for its groundbreaking mRNA technology, […]",
    "url": "https://finnhub.io/api/news?id=7d9acc9fb9f7ce24e47681affe6d76b8370e922154da81518601bf3324607be0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733011350,
      "headline": "Moderna, Inc. (MRNA): A Bull Case Theory",
      "id": 131729114,
      "image": "https://media.zenfs.com/en/insidermonkey.com/5a5cbe6584743e13eb260d64e6487235",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Moderna, Inc. (MRNA) on Substack by Natan. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc. (MRNA)’s share was trading at $42.05 as of Nov 26th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, a biotech leader renowned for its groundbreaking mRNA technology, […]",
      "url": "https://finnhub.io/api/news?id=7d9acc9fb9f7ce24e47681affe6d76b8370e922154da81518601bf3324607be0"
    }
  }
]